search
Back to results

Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion (CROSS-COBIS)

Primary Purpose

Coronary Artery Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Simple Crossover
Side branch opening
Sponsored by
Keimyung University Dongsan Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring Percutaneous coronary intervention, Bifurcation, Treatment strategy, Side branch

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: (1) Subject must be at least 19 years of age (2) Patients with non-left main bifurcation lesion (SB diameter ≥2.3 mm) (3) Target lesions amenable for 1-stenting with provisional SB approach by operators' decision (4) Angiographically compromised SB (visual SB stenosis ≥50%) after provisional MV stenting Exclusion Criteria: (1) Target lesions requiring elective 2-stenting technique by operators' decision (Observation Group 1)* (2) Patients who inevitably require SB intervention after MV stenting, as follows. (Observation Group 2)* Reduced SB TIMI flow (≤2) after MV stenting SB dissection after MV stenting (≥ Type C) (3) Patients without SB compromise after MV stenting (visually SB stenosis <50%) (Observation Group 3)* (4) Cardiogenic shock (Killip class IV) at presentation (5) Patients with significant valvular heart disease or severe left ventricular systolic dysfunction (ejection fraction <35%) (6) Pregnancy or breast feeding (7) Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment) (8) Unwillingness or inability to comply with the procedures described in this protocol

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Simple crossover arm

    Side branch opening arm

    Arm Description

    This arm will receive the main vessel stenting only (with proximal optimization technique).

    This arm will receive a side branch opening procedure after the main vessel stenting.

    Outcomes

    Primary Outcome Measures

    Target-lesion failure
    a composite of cardiac death, myocardial infarction, and target-lesion revascularization

    Secondary Outcome Measures

    All-cause death
    Death from any causes
    Cardiac death
    Death from cardiac causes
    Myocardial infarction
    any myocardial infarction
    Target-vessel myocardial infarction
    myocardial infarction in target-vessel
    Target-lesion revascularization
    Clinically indicated target-lesion revascularization
    Target-vessel revascularization
    Clinically indicated target-vessel revascularization
    Any revascularization
    Repeat revascularization procedure
    Stent thrombosis
    definite or probable stent thrombosis by Academic Research Consortium [ARC] definition
    Bleeding
    Bleeding ARC type 2, 3 or 5 bleeding
    Total procedure time
    procedure time
    Total amount of contrast use
    used contrast amount
    Incidence of contrast induced nephropathy
    defined as an increase in creatinine of ≥0.5mg/dL or ≥25% from baseline within 72 hours after contrast exposure

    Full Information

    First Posted
    December 19, 2022
    Last Updated
    January 26, 2023
    Sponsor
    Keimyung University Dongsan Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05705362
    Brief Title
    Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion
    Acronym
    CROSS-COBIS
    Official Title
    Randomized Controlled Trial of Simple CROSSsover Versus Side Branch Opening on Clinical Outcomes in Patients With Non-Left Main BIfurcation LeSion (CROSS-COBIS)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 1, 2023 (Anticipated)
    Primary Completion Date
    March 31, 2028 (Anticipated)
    Study Completion Date
    December 31, 2029 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Keimyung University Dongsan Medical Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Hypothesis: Simple crossover strategy would be non-inferior to SB opening strategy in the risk of target lesion failure (TLF) in patients with angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion. A total of 1000 patients (500 per each group) with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion will be enrolled. Patients will be randomized to either the simple crossover strategy group or SB opening strategy group at the time of enrollment with 1:1 ratio. Stratified randomization according to participating center, clinical presentation (acute coronary syndrome or stable ischemic heart disease), and type of bifurcation lesions (true or non-true) will be performed.
    Detailed Description
    Despite advances in stenting techniques and devices, percutaneous coronary intervention (PCI) for bifurcation lesions remains one of the most challenging and complex procedures. Current guidelines recommend 1-stenting with provisional side branch (SB) approach should be an initial treatment strategy for the bifurcation lesions, based on the previous results of several randomized trials. However, the standardization of the provisional strategy is limited. In particular, there is a recommendation on the treatment technique for SB when SB intervention is required, but It has not been decided in which cases SB treatment is necessary, in the latest European Bifurcation Club (EBC) consensus document.16 In previous studies, the criteria for performing SB opening after MV stent intervention in the 1-stenting with provisional SB approach were varied. In the DK-CUSH II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) or CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) trials, SB intervention was performed when the SB diameter stenosis more than 50%, grade B or higher dissection, or blood flow disturbance (TIMI flow 2 or less) after MV stent insertion. On the other hand, in the Nordic trial, the authors applied strict criteria for SB intervention after MV stent insertion (TIMI flow 2 or less only). Furthermore, there have been conflicting results regarding the clinical and angiographic outcomes of the jailed SB opening strategy after the main vessel (MV) stenting, compared with the simple crossover strategy for non-left main bifurcation lesion. On this background, this trial aims to compare the clinical outcomes between simple crossover and side branch opening strategies in patients with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Coronary Artery Disease
    Keywords
    Percutaneous coronary intervention, Bifurcation, Treatment strategy, Side branch

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    1000 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Simple crossover arm
    Arm Type
    Experimental
    Arm Description
    This arm will receive the main vessel stenting only (with proximal optimization technique).
    Arm Title
    Side branch opening arm
    Arm Type
    Active Comparator
    Arm Description
    This arm will receive a side branch opening procedure after the main vessel stenting.
    Intervention Type
    Procedure
    Intervention Name(s)
    Simple Crossover
    Intervention Description
    Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
    Intervention Type
    Procedure
    Intervention Name(s)
    Side branch opening
    Intervention Description
    According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
    Primary Outcome Measure Information:
    Title
    Target-lesion failure
    Description
    a composite of cardiac death, myocardial infarction, and target-lesion revascularization
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Secondary Outcome Measure Information:
    Title
    All-cause death
    Description
    Death from any causes
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Cardiac death
    Description
    Death from cardiac causes
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Myocardial infarction
    Description
    any myocardial infarction
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Target-vessel myocardial infarction
    Description
    myocardial infarction in target-vessel
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Target-lesion revascularization
    Description
    Clinically indicated target-lesion revascularization
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Target-vessel revascularization
    Description
    Clinically indicated target-vessel revascularization
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Any revascularization
    Description
    Repeat revascularization procedure
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Stent thrombosis
    Description
    definite or probable stent thrombosis by Academic Research Consortium [ARC] definition
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Bleeding
    Description
    Bleeding ARC type 2, 3 or 5 bleeding
    Time Frame
    up to 2 years of median follow-up (till 1 year after the last patient enrollment)
    Title
    Total procedure time
    Description
    procedure time
    Time Frame
    at 1 day
    Title
    Total amount of contrast use
    Description
    used contrast amount
    Time Frame
    at 1 day
    Title
    Incidence of contrast induced nephropathy
    Description
    defined as an increase in creatinine of ≥0.5mg/dL or ≥25% from baseline within 72 hours after contrast exposure
    Time Frame
    72 hours after the index procedure

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    19 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: (1) Subject must be at least 19 years of age (2) Patients with non-left main bifurcation lesion (SB diameter ≥2.3 mm) (3) Target lesions amenable for 1-stenting with provisional SB approach by operators' decision (4) Angiographically compromised SB (visual SB stenosis ≥50%) after provisional MV stenting Exclusion Criteria: (1) Target lesions requiring elective 2-stenting technique by operators' decision (Observation Group 1)* (2) Patients who inevitably require SB intervention after MV stenting, as follows. (Observation Group 2)* Reduced SB TIMI flow (≤2) after MV stenting SB dissection after MV stenting (≥ Type C) (3) Patients without SB compromise after MV stenting (visually SB stenosis <50%) (Observation Group 3)* (4) Cardiogenic shock (Killip class IV) at presentation (5) Patients with significant valvular heart disease or severe left ventricular systolic dysfunction (ejection fraction <35%) (6) Pregnancy or breast feeding (7) Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment) (8) Unwillingness or inability to comply with the procedures described in this protocol
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Chang-Wook Nam, MD
    Phone
    82-53-258-7019
    Email
    namcwcv@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ki Hong Choi
    Phone
    82-2-3410-6653
    Email
    cardiokh@gmail.com

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion

    We'll reach out to this number within 24 hrs